Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 2/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.51 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.46 |
| ▸ | MMP8 | P22894 | 2/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.43 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9925897 | 1.00 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL398539 | 1.00 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL14195836 | 1.00 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL1105501 | 1.00 | SLC1A3 (0.51) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL24815318 | 0.87 | SLC1A2 (0.53) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL7284299 | 0.87 | SLC1A2 (0.53) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL5556446 | 0.87 | SLC1A2 (0.53) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL24815315 | 0.87 | SLC1A2 (0.53) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL29178320 | 0.87 | SLC1A2 (0.53) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 | |
| SCHEMBL21122288 | 0.86 | NPC1 (0.54) | SLC1A3SLC1A2SLC1A1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295402-B1 | Antibacterial agents | UNIV WASHINGTON (US) | 2015-08-12 | — | — | EP | disclosed |
| EP-1618087-B1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
| US-20060154988-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | SLC1A3 3952/4885SLC1A2 3933/4885SLC1A1 3289/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | SLC1A3 3952/4885SLC1A2 3933/4885SLC1A1 3289/4885 |
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | SLC1A3 3952/4885SLC1A2 3933/4885SLC1A1 3289/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | SLC1A3 3952/4885SLC1A2 3933/4885SLC1A1 3289/4885 |
| US-20060154988-A1 | Antibacterial agents | MRPL21, SI, PGLS | SLC1A3 3952/4885SLC1A2 3933/4885SLC1A1 3289/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | SLC1A3 3952/4885SLC1A2 3933/4885SLC1A1 3289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.